Tilde Sciences acquires Daraprim® and Vecamyl® from Vyera Pharmaceuticals
2023-12-07
NEWARK, N.J., Dec. 7, 2023 /PRNewswire/ -- Tilde Sciences, a specialty pharmaceutical company, announced today that it has acquired two medicines, Daraprim® and Vecamyl® from Vyera Pharmaceuticals.
Tilde Sciences expects a seamless transition from Vyera Pharmaceuticals and uninterrupted access through Optime Care, its specialty pharmacy partner. Tilde has elected to use Optime Care because of the company's commitment to provide patients and their caregivers with dedicated programs and services in support of these important drugs.
If you have any questions about Daraprim® or the financial assistance programs available, call1-877-258-2033 and press 3, or visit www.daraprimdirect.com. Eligible patients who have commercial insurance may pay as little as $0 out-of-pocket for their prescription.1
Questions related to Vecamyl® should be directed to 1-877-794-0008 or visit www.vecamyl.com.
About Tilde
Tilde Sciences is a United States based biopharmaceutical company specializing in the development and commercialization of specialty pharmaceuticals tailored for rare diseases with significant unmet needs. For more information visit https://www.tildesciences.com/.
1 Financial assistance programs are subject to terms and conditions and patient eligibility requirements. Restrictions, including where prohibited by law, may apply. Offers are subject to change or discontinuation without notice. Financial assistance programs are not insurance nor are they intended to be a substitute for insurance.
SOURCE Tilde Sciences LLC
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。